Rella C, Coviello M, Quaranta M, Paradiso A
Hematology and Hemostatis Laboratory, Oncology Institute, Bari, Italy.
Thromb Res. 1993 Jan 15;69(2):209-20. doi: 10.1016/0049-3848(93)90046-q.
The relationship between tissue-type plasminogen activator (t-PA) antigen content and receptor status was investigated in 200 human breast cancer cytosols to evaluate the efficacy of t-PA as a marker of functional steroid receptors. t-PA level was measured by an enzyme-linked immunoassay (ELISA) and estrogen (ER) and progesterone (PgR) receptors were assayed by the DCC method. A highly significant correlation was found between t-PA levels and receptor status. The mean +/- SE enzyme content was 13.5 +/- 2.9 in ER+ tumors and 1.8 +/- 0.3 ng/mg protein in ER- tumors; the enzyme content in PgR+ tumors was 14.2 +/- 3.3 and 3.4 +/- 1.4 ng/mg protein in PgR- tumors. When tumors were divided into four subgroups according to receptor content (ER+PgR+, ER+PgR-, ER-PgR+, and ER-PgR-), t-PA concentration was able to differentiate these groups. Also, t-PA level was compared to several clinical variables; it was not correlated with menopausal status or lymph node involvement. However, t-PA content varied according to tumor size. Our data shows that t-PA content in tumor cytosols is statistically related to receptor status and that determination of t-PA levels in breast cancer might furnish additional information as to the functional state of the receptors which may be necessary for planning hormone therapy.
在200份人乳腺癌细胞溶质中研究了组织型纤溶酶原激活剂（t-PA）抗原含量与受体状态之间的关系，以评估t-PA作为功能性类固醇受体标志物的有效性。通过酶联免疫吸附测定（ELISA）测量t-PA水平，通过葡聚糖包被活性炭（DCC）法检测雌激素（ER）和孕激素（PgR）受体。发现t-PA水平与受体状态之间存在高度显著的相关性。ER阳性肿瘤的平均±标准误酶含量为13.5±2.9，ER阴性肿瘤为1.8±0.3 ng/mg蛋白质；PgR阳性肿瘤的酶含量为14.2±3.3，PgR阴性肿瘤为3.4±1.4 ng/mg蛋白质。当根据受体含量将肿瘤分为四个亚组（ER+PgR+、ER+PgR-、ER-PgR+和ER-PgR-）时，t-PA浓度能够区分这些组。此外，将t-PA水平与几个临床变量进行了比较；它与绝经状态或淋巴结受累无关。然而，t-PA含量根据肿瘤大小而变化。我们的数据表明，肿瘤细胞溶质中的t-PA含量与受体状态在统计学上相关，并且测定乳腺癌中的t-PA水平可能会提供有关受体功能状态的额外信息，这对于规划激素治疗可能是必要的。
